Corporate Banner
Satellite Banner
Scientific Communities
Become a Member | Sign in
Home>News>This Article

Integromics Partners with CITRE and CEIT

Published: Friday, April 19, 2013
Last Updated: Friday, April 19, 2013
Bookmark and Share
Venture attracts EUR 2 million grant for ‘new frontier’ of data interpretation for drug development.

Integromics® has announced that it has entered into a partnership with the Celgene Institute for Translational Research Europe (CITRE) and the Centre of Studies and Technical Research (CEIT), for the execution of SANSCRIPT, a project that aims at the development of new data analysis methods applied in clinical genomics studies.

Based on the strength of its R&D work, the new partnership has been awarded a EUR two million grant from the Spanish Government for the development of algorithms and statistical tools to identify alternative splicing events significantly related with disease associated biomarkers or therapeutic targets using RNA sequencing (RNA-seq).

Current algorithms, due to their intrinsic characteristics, have major limitations in characterizing gene alterations, which are frequently related to drug resistance and other phenotypes.

Therefore, it is essential to adapt the present methods developed for the new massive sequencing technologies to extract all their potential for development of diagnostic and prognostic tests, and drug discovery in the clinical and pharmaceutical environment.

The SANSCRIPT collaboration, coordinated by Integromics, has been designed to address these issues through the synergy between the engineers at CEIT, scientists at CITRE and the bioinformaticians from Integromics, which will undoubtedly accelerate the development of solutions for personalized medicine.

The new solutions will be validated for personalized-drug development processes where gene expression is essential to understand the differing responses to treatment.

The SANSCRIPT project represents an ideal opportunity for Integromics to reinforce its commitment to the development of software solutions for personalized medicine in the context of clinical studies.

“This is the first time that we can effectively work hand in hand with both an advanced software engineering team from a first class Technical Center and a research group from a leading biopharmaceutical corporation to cooperatively address an important gap”, said Eduardo González Couto, Chief Strategy Officer, Integromics. “The SANSCRIPT grant provides key financial support for us to spearhead the usage of NGS for drug development and help us make personalized medicine a reality.”

“Automated next-gen sequencers have increased the speed and reduced the cost of sequencing, making it possible to offer genetic testing to consumers. Producing the genomic data is not a problem anymore, while the analysis and interpretation of this data has become the ‘new hurdle’ ”, continues Dr. Gonzalez Couto.

Dr. Couto continued, “In order to identify the gene expression changes associated to sensitivity to treatment, including the detailed characterization of transcription isoforms for clinical usage, bioinformatics tools are crucially needed to design novel algorithms from the very beginning to be compatible with long reads from upcoming NGS technologies.”

"For us it is a pleasure to work with both a leading Spanish biosoftware company and a Pharma industry. This collaboration will help us to focus on a specific problem and provide a solution: algorithms that identify gene aberrations related to drug resistance in cancer” said Prof. Angel Rubio, Principal Investigator of the CEIT.

Prof. Rubio continued, “We are quite excited in working to improve the health: even though we have had other projects related with human health, they were not so ambitious as this one” concluded Prof. Rubio.

As genome sequencing continues to take footholds in diagnosis, prognosis and treatment of diseases, it is expected that the findings of the SANSCRIPT project, in terms of software and new methodologies, will enhance the reliability and significance of the next generation sequencing (NGS) technology in the pipelines of drug development and clinical genomics studies.

The results of SANSCRIPT will be made available through new releases of the Integromics’ OmicsOffice® software suite.

This will give clinical drug discovery scientists an immediate access to the fruits of the SANSCRIPT project, allowing them to apply new data analysis methods to their own studies.

Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More Than 5,100+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Integromics Invests in the Optimization of Computing Performance for Bioinformatics Applications
Key collaboration with European experts of HPC to bring new big-data computing solutions into genomics.
Friday, March 22, 2013
Integromics Partners with FPGMX to Develop Low-Cost Methods for Clinical Genomics
Venture attracts EUR one million grant for ‘new frontier’ of data interpretation for medical usage.
Tuesday, February 07, 2012
Integromics and Ingenuity Expand their Co-operation with the Integration of a Fourth Integromics Product to Ingenuity’s IPA
Combined solutions to offer bridge between discovery and relevance of genomics and proteomics.
Thursday, April 07, 2011
Novel Polyadenylation Genome-wide Profiling Achieved using Next Generation Sequencing Software
A paper published in the journal Cell highlighting a novel genome wide profile of polyadenylation events in human and yeast, performed with Direct RNA Sequencing, demonstrated the importance of appropriate bioinformatics software in maximizing the value of the genomic data.
Monday, January 10, 2011
Integromics and TATAA Biocenter Collaborate to offer Comprehensive qPCR Data Analysis
The TATAA Biocenter is recommending Integromics’ RealTime StatMiner® as a complete solution for qPCR data analysis.
Monday, March 08, 2010
Integromics S.L. Integrates GeneBio’s Phenyx within OmicsHub Proteomics
Geneva Bioinformatics (GeneBio) SA and Integromics S.L. today announced that GeneBio's Phenyx software platform for MS data analysis has been successfully integrated into Integromics’ latest proteomics data analysis and management tool - OmicsHub Proteomics. This integration gives Phenyx and OmicsHub Proteomics users the possibility of combining results from different search engines thereby increasing the accuracy of the protein identification process.
Wednesday, September 23, 2009
Scientific News
Integrated Omics Analysis
Studying multi-omics promises to give a more holistic picture of the organism and its place in its ecosystem, however despite the complexities involved those within the field are optimistic.
Unravelling the Role of Key Genes and DNA Methylation in Blood Cell Malignancies
Researchers from the University of Nebraska Medical Center have demonstrated the role of Dnmt3a in safeguarding normal haematopoiesis.
Salford Lung Study - The First Real World Clinical Trial
In this podcast, we learn about the Salford Lung Study and its potential to revolutionize the way we assess new drugs and treatments around the world.
Point of Care Diagnostics - A Cautious Revolution
Advances in molecular biology, coupled with the miniaturization and improved sensitivity of assays and devices in general, have enabled a new wave of point-of-care (POC) or “bedside” diagnostics.
Mass Spec Technology Drives Innovation Across the Biopharma Workflow
With greater resolving power, analytical speed, and accuracy, new mass spectrometry technology and techniques are infiltrating the biopharmaceuticals workflow.
NIH Study Determines Key Differences between Allergic and Non-Allergic Dust Mite Proteins
Researchers at NIH have uncovered factors that lead to the development of dust mite allergy and assist in the design of better allergy therapies.
New Mechanism of Plant RNA Degradation Identified
Researchers have identified a novel mechanism by which RNA is degraded.
Achieving “Green” Desalination
Workshop explores ways to reduce or eliminate the carbon footprint of seawater desalination plants.
NIH Contributes to Global Effort to Prevent and Manage Lung Diseases
The large scale trial will measure health benefits of clean cookstoves.
Study Finds Key Regulator in Pulmonary Fibrosis
Researchers identify an enzyme that could open the way to therpies for chronic fatal lung disease.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,100+ scientific videos